Unicycive Therapeutics, Inc.
UNCY
$4.44
-$0.31-6.53%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 105.80% | 143.23% | 91.01% | 24.94% | 23.26% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -5.92% | -13.21% | 46.70% | 5.27% | 71.24% |
| Operating Income | 5.92% | 13.21% | -46.70% | -5.27% | -71.24% |
| Income Before Tax | -165.42% | 102.72% | -176.03% | 5.47% | 356.77% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -165.42% | 102.72% | -176.03% | 5.47% | 356.77% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -165.42% | 102.72% | -176.03% | 5.47% | 356.77% |
| EBIT | 5.92% | 13.21% | -46.70% | -5.27% | -71.24% |
| EBITDA | 6.00% | 13.21% | -46.66% | -5.21% | -71.32% |
| EPS Basic | -113.34% | 100.56% | 8.99% | 65.89% | 234.75% |
| Normalized Basic EPS | -120.16% | 100.81% | 8.99% | 65.32% | 203.18% |
| EPS Diluted | 64.20% | 93.54% | 8.99% | 65.89% | 49.79% |
| Normalized Diluted EPS | -150.01% | 100.77% | 8.99% | 65.32% | 141.59% |
| Average Basic Shares Outstanding | 224.47% | 234.91% | 203.29% | 172.56% | 148.87% |
| Average Diluted Shares Outstanding | 30.80% | 255.02% | 203.29% | 172.56% | 517.35% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |